2023
Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States.
Goshua G, Calhoun C, Ito S, James L, Luviano A, Krishnamurti L, Pandya A. Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States. Annals Of Internal Medicine 2023, 176: 779-787. PMID: 37247420, PMCID: PMC10370480, DOI: 10.7326/m22-3272.Peer-Reviewed Original Research
2022
Enrollment Lessons from a Biological Assignment Study of Marrow Transplantation versus Standard Care for Adolescents and Young Adults with Sickle Cell Disease: Considerations for Future Gene and Cellular Therapy Trials
Krishnamurti L, Neuberg D, Sullivan K, Smith S, Eapen M, Walters M. Enrollment Lessons from a Biological Assignment Study of Marrow Transplantation versus Standard Care for Adolescents and Young Adults with Sickle Cell Disease: Considerations for Future Gene and Cellular Therapy Trials. Transplantation And Cellular Therapy 2022, 29: 217-221. PMID: 36270432, PMCID: PMC10539686, DOI: 10.1016/j.jtct.2022.10.008.Peer-Reviewed Original ResearchConceptsBone marrow transplantationSickle cell diseaseMarrow transplantationNonmalignant diseasesCell diseaseAdult sickle cell diseaseMyeloablative bone marrow transplantationSingle-arm feasibility studyYoung adultsCellular therapy trialsMulticenter National InstituteRegimen-related toxicitySingle-arm studyFrequency of HLACoronavirus disease 2019 (COVID-19) pandemicAcademic medical centerDisease 2019 pandemicShort-term endpointsBMT centersBMT regimenCare armPain episodesPrimary endpointStandard careCurative therapyAssociated comorbidities, healthcare utilization & mortality in hospitalized patients with haemophilia in the United States: Contemporary nationally representative estimates
Day J, Takemoto C, Sharathkumar A, Makhani S, Gupta A, Bitner S, Josephson C, Bloch E, Tobian A, Krishnamurti L, Goel R. Associated comorbidities, healthcare utilization & mortality in hospitalized patients with haemophilia in the United States: Contemporary nationally representative estimates. Haemophilia 2022, 28: 532-541. PMID: 35412659, PMCID: PMC9540439, DOI: 10.1111/hae.14557.Peer-Reviewed Original ResearchConceptsNationwide Inpatient SampleHealthcare utilizationPrevalence of comorbiditiesAge-related comorbiditiesCentral line infectionsInpatient discharge databaseOverall mortality rateCatheter-related infectionsHealthcare utilization patternsMedian hospital chargesICD-10 codesRepresentative estimatesCause admissionsCause hospitalizationAdult PWHAssociated comorbidityCommon comorbiditiesHospitalized patientsMedian ageContemporary cohortHospital burdenHospital chargesDischarge databaseInpatient SampleLine infections
2021
Hematopoietic Cell Transplantation Outcomes among Medicaid and Privately Insured Patients with Sickle Cell Disease
Mupfudze T, Meyer C, Preussler J, Mau L, Bolon Y, Steinert P, Arnold S, Saber W, Krishnamurti L. Hematopoietic Cell Transplantation Outcomes among Medicaid and Privately Insured Patients with Sickle Cell Disease. Transplantation And Cellular Therapy 2021, 27: 685.e1-685.e8. PMID: 33895405, PMCID: PMC8680220, DOI: 10.1016/j.jtct.2021.04.009.Peer-Reviewed Original ResearchConceptsEvent-free survivalSickle cell diseaseHematopoietic cell transplantation outcomesSignificant between-group differencesGraft failureOverall survivalChronic GVHDCell transplantation outcomesBetween-group differencesAcute GVHDCumulative incidenceAlloHCT outcomesTransplantation outcomesInsurance statusCell diseaseAllogeneic hematopoietic cell transplantation outcomesLower event-free survivalPrivate insuranceRecipients of MedicaidProportion of patientsRetrospective multicenter studyKaplan-Meier methodPrivate insurance groupMarrow Transplant ResearchHealth insurance statusGaps in Medicaid Coverage and Financial Toxicity: A Health Disparity in Hematopoietic Cell Transplantation for Sickle Cell Disease
Krishnamurti L. Gaps in Medicaid Coverage and Financial Toxicity: A Health Disparity in Hematopoietic Cell Transplantation for Sickle Cell Disease. Transplantation And Cellular Therapy 2021, 27: 284-285. PMID: 33836866, DOI: 10.1016/j.jtct.2021.03.016.Peer-Reviewed Original Research
2019
Comparative Effectiveness of a Web-Based Patient Decision Aid for Therapeutic Options for Sickle Cell Disease: Randomized Controlled Trial
Krishnamurti L, Ross D, Sinha C, Leong T, Bakshi N, Mittal N, Veludhandi D, Pham A, Taneja A, Gupta K, Nwanze J, Matthews A, Joshi S, Olivieri V, Arjunan S, Okonkwo I, Lukombo I, Lane P, Bakshi N, Loewenstein G. Comparative Effectiveness of a Web-Based Patient Decision Aid for Therapeutic Options for Sickle Cell Disease: Randomized Controlled Trial. Journal Of Medical Internet Research 2019, 21: e14462. PMID: 31799940, PMCID: PMC6934048, DOI: 10.2196/14462.Peer-Reviewed Original ResearchConceptsRandomized clinical trialsPatient decision aidSickle cell diseaseWeb-based patient decision aidClinical trialsHealth care providersCell diseaseDecisional conflictPatient knowledgeCare providersDecision aid armStandard care armOttawa Decision Support FrameworkChronic blood transfusionsDisease-modifying therapiesBone marrow transplantationDecision aidCare armDecision aid prototypeClinical characteristicsBlood transfusionControlled TrialsPediatric patientsMarrow transplantationTherapeutic optionsManagement of Chronic Pain in Adults Living With Sickle Cell Disease in the Era of the Opioid Epidemic
Sinha C, Bakshi N, Ross D, Krishnamurti L. Management of Chronic Pain in Adults Living With Sickle Cell Disease in the Era of the Opioid Epidemic. JAMA Network Open 2019, 2: e194410. PMID: 31125105, PMCID: PMC6632133, DOI: 10.1001/jamanetworkopen.2019.4410.Peer-Reviewed Original ResearchConceptsSickle cell diseaseOpioid epidemicOpioid usePain managementChronic painAlternative therapiesCell diseaseAfrican American race/ethnicityDisease controlVaso-occlusive painPain medication useChronic pain managementSickle cell clinicCurrent opioid epidemicRace/ethnicityOpioid dosingOpioid dosageOpioid prescriptionsAdult patientsMedian ageMedication usePersistent painComprehensive careMAIN OUTCOMEPain
2014
Risk Factors for Death in 632 Patients with Sickle Cell Disease in the United States and United Kingdom
Gladwin M, Barst R, Gibbs J, Hildesheim M, Sachdev V, Nouraie M, Hassell K, Little J, Schraufnagel D, Krishnamurti L, Novelli E, Girgis R, Morris C, Rosenzweig E, Badesch D, Lanzkron S, Castro O, Taylor J, Goldsmith J, Kato G, Gordeuk V, Machado R, Investigators and Patients O. Risk Factors for Death in 632 Patients with Sickle Cell Disease in the United States and United Kingdom. PLOS ONE 2014, 9: e99489. PMID: 24988120, PMCID: PMC4079316, DOI: 10.1371/journal.pone.0099489.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnemia, Sickle CellBlood Flow VelocityBlood PressureCohort StudiesCreatinineFemaleFerritinsFollow-Up StudiesHemolysisHumansHypertension, PulmonaryKaplan-Meier EstimateMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsProportional Hazards ModelsRisk FactorsSeverity of Illness IndexUnited KingdomUnited StatesWalkingConceptsTricuspid regurgitation velocitySickle cell diseaseNT-proBNPCell diseaseMean pulmonary artery pressurePg/Pulmonary artery systolic pressurePulmonary artery pressureRisk of deathCause of mortalityPositive predictive valuePg/mLArtery pressurePulmonary hypertensionChronic transfusionScreening cohortHemolytic markersSystolic pressureCumulative survivalMale genderRisk factorsHigh riskPredictive valueClass IIIPatients
2013
Analysis of national and single-center incidence and survival after liver transplantation for hepatoblastoma: New trends and future opportunities
Cruz R, Ranganathan S, Mazariegos G, Soltys K, Nayyar N, Sun Q, Bond G, Shaw P, Haberman K, Krishnamurti L, Marsh J, Humar A, Sindhi R. Analysis of national and single-center incidence and survival after liver transplantation for hepatoblastoma: New trends and future opportunities. Surgery 2013, 153: 150-159. PMID: 23331862, DOI: 10.1016/j.surg.2012.11.006.Peer-Reviewed Original ResearchConceptsTumor histologyLiver transplantationNational Cancer Institute's SurveillanceFavorable tumor histologyHepatic artery thrombosisEnd Results registryUnresectable liver malignanciesDeterminants of survivalLTx centersPosttransplantation outcomesArtery thrombosisNonmalignant indicationsPulmonary metastasesSurgical resectionChildren's HospitalPatient survivalTumor lysisUnited NetworkLiver malignanciesTumor necrosisAntithrombotic agentsOrgan SharingHepatoblastoma casesLTxStage III
2012
The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe
Nouraie M, Lee J, Zhang Y, Kanias T, Zhao X, Xiong Z, Oriss T, Zeng Q, Kato G, Gibbs J, Hildesheim M, Sachdev V, Barst R, Machado R, Hassell K, Little J, Schraufnagel D, Krishnamurti L, Novelli E, Girgis R, Morris C, Rosenzweig E, Badesch D, Lanzkron S, Castro O, Goldsmith J, Gordeuk V, Gladwin M. The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica 2012, 98: 464-472. PMID: 22983573, PMCID: PMC3659937, DOI: 10.3324/haematol.2012.068965.Peer-Reviewed Original ResearchConceptsRisk of deathSickle cell diseaseSickle cell anemiaClinical outcomesHemolytic componentPulse pressureCell diseaseOxygen saturationCell anemiaDirect markerRed blood cell microparticlesCutaneous leg ulcerationTricuspid regurgitation velocityIndependent risk factorCell-free hemoglobin concentrationsPulmonary systolic pressureVentricular diastolic dimensionSerum lactate dehydrogenaseSystemic pulse pressureLowest oxygen saturationTwo-year followHemoglobin SS patientsTotal bilirubin concentrationCertain clinical complicationsHigh hemoglobin FMortality, health care utilization and associated diagnoses in hospitalized patients with haemophilia in the United States: first reported nationwide estimates
GOEL R, KRISHNAMURTI L. Mortality, health care utilization and associated diagnoses in hospitalized patients with haemophilia in the United States: first reported nationwide estimates. Haemophilia 2012, 18: 688-692. PMID: 22500777, DOI: 10.1111/j.1365-2516.2012.02774.x.Peer-Reviewed Original ResearchConceptsNational Inpatient SampleCentral line infectionsHospital mortalityHospital dischargeLine infectionsHemophilia AMean hospital chargesCause of hospitalizationHealth care utilizationGeneral male populationDiagnosis of hemophiliaAge-related illnessesStratified probability sampleHepatitis CRespiratory failureHeart failureIntraventricular hemorrhageMedian ageAge of mortalityCare utilizationHospital chargesIntracranial hemorrhageNeonatal periodPediatric deathsHepatic coma
2011
Echocardiographic Markers of Elevated Pulmonary Pressure and Left Ventricular Diastolic Dysfunction Are Associated With Exercise Intolerance in Adults and Adolescents With Homozygous Sickle Cell Anemia in the United States and United Kingdom
Sachdev V, Kato G, Gibbs J, Barst R, Machado R, Nouraie M, Hassell K, Little J, Schraufnagel D, Krishnamurti L, Novelli E, Girgis R, Morris C, Rosenzweig E, Badesch D, Lanzkron S, Castro O, Taylor J, Hannoush H, Goldsmith J, Gladwin M, Gordeuk V. Echocardiographic Markers of Elevated Pulmonary Pressure and Left Ventricular Diastolic Dysfunction Are Associated With Exercise Intolerance in Adults and Adolescents With Homozygous Sickle Cell Anemia in the United States and United Kingdom. Circulation 2011, 124: 1452-1460. PMID: 21900080, PMCID: PMC3183314, DOI: 10.1161/circulationaha.111.032920.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnemia, Sickle CellChildEchocardiographyExercise TestExercise ToleranceFamilial Primary Pulmonary HypertensionFemaleHomozygoteHumansHypertension, PulmonaryMaleMiddle AgedMultivariate AnalysisPredictive Value of TestsProspective StudiesPulmonary ArteryTricuspid Valve InsufficiencyUnited KingdomUnited StatesVentricular Dysfunction, LeftYoung AdultConceptsTricuspid regurgitation velocitySickle cell diseaseSickle cell anemiaVentricular diastolic dysfunctionDiastolic dysfunctionCell diseaseCell anemiaPulmonary hypertensionExercise capacityWalk distanceElevated pulmonary artery systolic pressurePulmonary artery systolic pressureSystolic pulmonary artery pressureHomozygous sickle cell anemiaPulmonary pressure elevationLV diastolic dysfunctionLV filling pressurePoor exercise capacityPulmonary artery pressureElevated pulmonary pressuresLong-term outcomesHomozygous hemoglobin SBlood urea nitrogenArtery pressureEchocardiographic markers